2 results
Use and experience with six-monthly paliperidone in the Campo de Gibraltar area. Descriptive study.
- C. M. Gil Sánchez, J. A. Salomón Martínez, E. Corbacho Navarro
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, pp. S1005-S1006
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Long-acting injectable antipsychotics have demonstrated advantages over therapeutic adherence and can reduce the rates of relapses and due to treatment discontinuation. The novel presentation of paliperidone palmitate six-month (PP6M) can simplify the treatment to two injections per year.
ObjectivesThe purpose of the present research is to describe the profile of patients receiving this novel treatment in our area. For this, a descriptive study has been carried out.
MethodsWe have collected and analyzed data from a total of 8 patients from the global long-acting injectable nursing registry in our area. The data collection was from May 2022 to October 2022.
ResultsID Patient Age Gender Medical comorbidities Social support Adherence to previous LAI EP001AGC 52 M No - Yes EP002EGA 53 M No Low No EP003ESL 45 F Yes HIV, HCV, dyslipidemia, Enough Yes EP004ACG 60 M Yes Hypertension, dyslipidemia Good Yes EP005DCP 52 M Yes COPD Enough Yes EP006ATT 47 M No Enough / Low Yes EP007AH 40 F Yes Tension headache Enough Yes EP008IAR 66 F Yes Type 2 diabetes mellitus, hypertension, hyperuricemia Enough Yes ID Patient Diagnosis Refractory positive symptoms Last H. Polypharmacy Previous injection Injection date / Dose H. / Side Effects EP001AGC Paranoid schizophrenia - 08/03/2014 No PP3M 525mg 17/05/22 1.000 mg No EP002EGA Schizoaffective disorder Yes 19/08/2022 Yes Valproic acid 1.000mg PP1M 150mg (once) 13/09/22 1.000mg No EP003ESL Paranoid schizophrenia No 17/04/2019 Yes Olanzapine 10mg BZD PP3M 525mg 10/08/22 1.000mg Sedation (low) EP004ACG Paranoid schizophrenia No - Yes Quetiapine 50mg PP3M 525mg 16/09/22 1.000mg No EP005DCP Paranoid schizophrenia No 16/01/2004 Yes Olanzapine 20mg BZD PP3M 525mg 11/10/22 1.000mg No EP006ATT Persistent delusional disorder Yes - No PP3M 525mg 19/09/22 1.000mg No EP007AH Paranoid schizophrenia No 2017 No PP3M 525mg 03/08/22 1.000mg No EP008IAR Persistent delusional disorder Yes - Yes BZD Paliperidone oral 9mg and later PP3M 350mg (twice) 18/10/22 1.000mg No Fig. 1: Sociodemographic characteristics and Fig. 2: Clinical characteristics.
ConclusionsNone of the patients required hospitalization at the time of the study, although this work team considers that it is early to make conclusions in this regard. No serious or minor adverse effects were reported in any of the cases during the time of the investigation, apart from one case of mild sedation.
The clinical characteristics of most patients were psychopathological stability and good adherence to previous treatment. Although this study shows that the drug was also used in patients who did not meet these characteristics, specially one case of poor social support. The data collected show that the profile of the patient in whom the drug has been prescribed can be varied and broad.
Disclosure of InterestNone Declared
Delusions of body control: Psychopathological description of a case.
- C. M. Gil Sánchez, J. A. Salomón Martínez, E. Fernández García
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, pp. S999-S1000
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
A considerable number of patients with schizophrenia suffer from somatic passivity or delusions of control. So much so, that Schneider considered them as part of the first-rank symptoms.
In these cases, patients can think that feelings, impulses, thoughts, or actions are controlled or imposed by an external force.
ObjectivesThe objective is to make a psychopathological description of this symptomatology, based on a case report with Anomalous bodily experiences.
MethodsIn this study, we describe the case of a patient with disorder of self-experience. We have conducted a systematic review of the descriptions published to date, regarding this case.
ResultsWe present the case of a 21-year-old patient who had gone to the emergency services three times for somatic pathology (described as dysesthetic and algic sensations in the throat, stomach and testicles).
In the psychopathological exploration, a delusional narrative is observed, as he refers that these sensations are being provoked by external people, with the aim of harming him.
The patient reports that these people are causing an increase in salivation in his salivary glands, for which he spits repeatedly.
He explains that these people can control his organs using an influencing machine, which in this case consists of a microchip implanted at the retroauricular area, from which they give orders and insult him at the same time.
In this case, a good symptom response was achieved with intramuscular Aripiprazole.
ConclusionsIn the experiences of passivity, the patient experiences one event as if it were not his, but inserted into his self from the outside.
In the case of somatic passivity, there is a belief that there are external influences acting on the body. In this case, there was probably a kinesthetic hallucination coupled with an experience of passivity.
Similar to other published cases, this patient complained of being controlled and impaired by some form of contemporary technology. Delusions of control are often associated with delusional explanations about how thought or body can be controlled, in this case, through a microchip.
Disclosure of InterestNone Declared